Newly issued patent claims provide patent protection into 2033

 

VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 20, 2017 -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued to DelMar, United States Patent No. 9,759,698 covering improved analytical methods for analyzing and determining impurities in dianhydrogalactitol (VAL-083).

TORONTO, ONTARIO--(Sept. 19, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that it has entered into a license agreement with South Carolina Research Foundation ("SCRF"), under which Revive will acquire an exclusive license from SCRF to develop and commercialize a portfolio of patents based on cannabinoid-based therapeutics, such as Cannabidiol, in the treatment of liver diseases.

Sustained safety observed over 48 weeks of treatment

Beneficial clinical effects in liver sustained over 48 weeks of treatment

Positive results support requests for meetings with both FDA and EMA to define the clinical-regulatory pathway for approval of PBI-4050 for the treatment of Alström syndrome

 

LAVAL, QC, Sept. 19, 2017 - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that longer-term data from its on-going phase 2 open label clinical trial in subjects suffering from Alström Syndrome in the United Kingdom confirm that the beneficial clinical effects previously observed are sustained during prolonged treatment.

NEW YORK, Sept. 18, 2017  -- iBio, Inc. (NYSE AMERICAN:IBIO) – iBio, with its subsidiary, iBio CDMO LLC in Bryan/College Station, Texas ("iBio CDMO"), has partnered with TheoremDx, Inc., in Edina, Minnesota, to develop proteins for rapid diagnostic testing products.

 

The collaboration will leverage the TheoremDx point-of-care diagnostic system and the protein development and manufacturing capabilities of iBio. The goal of the collaboration is to serve the citizens of the US and the world through the rapid development and manufacturing of proprietary plant proteins for point-of-care diagnostic testing products.